Shanghai Hile Bio-Technology Co., Ltd. (SHA:603718)
China
· Delayed Price · Currency is CNY 3.900
+0.050 (1.30%)
Apr 29, 2026, 3:54 PM CST
SHA:603718 Revenue
In the year 2025, Shanghai Hile Bio-Technology had annual revenue of 187.87M CNY, down -30.69%. Shanghai Hile Bio-Technology had revenue of 38.13M in the quarter ending December 31, 2025, a decrease of -60.53%.
Revenue
187.87M
Revenue Growth
-30.69%
P/S Ratio
13.53
Revenue / Employee
513.31K
Employees
366
Market Cap
2.54B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 187.87M | -83.17M | -30.69% |
| Dec 31, 2024 | 271.04M | 30.32M | 12.59% |
| Dec 31, 2023 | 240.72M | -59.27M | -19.76% |
| Dec 31, 2022 | 299.99M | -47.30M | -13.62% |
| Dec 31, 2021 | 347.29M | 88.16M | 34.02% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Cabio Biotech (Wuhan) | 418.18M |
| Suzhou Fushilai Pharmaceutical | 412.51M |
| Shanghai Universal Biotech | 1.07B |
| Shandong Sito Bio-technology | 954.76M |
| Zhejiang East Asia Pharmaceutical | 940.19M |
| Jilin Jian Yisheng Pharmaceutical | 659.66M |
| Hubei Goto Biopharm | 626.28M |
| Guiyang Xintian Pharmaceutical | 749.72M |